Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
nect Biopharma (US:CNTB) Globenewswireยท2025-07-21 13:00"The termination of our ADR program is a meaningful step in our evolution to becoming a U.S.-centric company. The conversion from ADRs to directly listing our ordinary shares on Nasdaq will better facilitate institutional visibility, eliminate ADR depositary fees, and strengthen our ability to expand our investor base," said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. "These changes, in conjunction with the progress we have made in our rapid Phase 2 clinical development program for rademik ...